v3.25.4
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Private Placement [Member]
Preferred Stock [Member]
Private Placement [Member]
Common Stock [Member]
Private Placement [Member]
Additional Paid-in Capital [Member]
Private Placement [Member]
AOCI Attributable to Parent [Member]
Private Placement [Member]
Retained Earnings [Member]
Private Placement [Member]
Public Placement [Member]
Preferred Stock [Member]
Public Placement [Member]
Common Stock [Member]
Public Placement [Member]
Additional Paid-in Capital [Member]
Public Placement [Member]
AOCI Attributable to Parent [Member]
Public Placement [Member]
Retained Earnings [Member]
Public Placement [Member]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Balances (in shares) at Jun. 30, 2024                         0 39,254,643        
Balances at Jun. 30, 2024                         $ 0 $ 392,546 $ 245,140,758 $ 509,936 $ (215,843,575) $ 30,199,665
Exercise of stock options, RSUs & RSAs, net (in shares)                         0 70,309        
Exercise of stock options, RSUs & RSAs, net                         $ 0 $ 703 (703) 0 0 0
Issuance of common stock for acquisition of Visimid (in shares)                         0 279,553        
Issuance of common stock for acquisition of Visimid                         $ 0 $ 2,796 318,562 0 0 321,358
Stock-based compensation on stock options, RSUs & RSAs                         0 0 264,475 0 0 264,475
Foreign currency translation adjustment                         0 0 0 271,594 0 271,594
Net loss                         $ 0 $ 0 0 0 (1,622,745) (1,622,745)
Balances (in shares) at Sep. 30, 2024                         0 39,612,737        
Balances at Sep. 30, 2024                         $ 0 $ 396,127 245,733,382 781,530 (217,466,320) 29,444,719
Employee Stock Purchase Plan (in shares)                         0 8,232        
Employee Stock Purchase Plan                         $ 0 $ 82 10,290 0 0 10,372
Balances (in shares) at Jun. 30, 2024                         0 39,254,643        
Balances at Jun. 30, 2024                         $ 0 $ 392,546 245,140,758 509,936 (215,843,575) 30,199,665
Foreign currency translation adjustment                                   (179,441)
Net loss                                   (4,234,742)
Balances (in shares) at Dec. 31, 2024                         0 39,890,834        
Balances at Dec. 31, 2024                         $ 0 $ 398,908 246,051,852 330,495 (220,078,317) 26,702,938
Balances (in shares) at Sep. 30, 2024                         0 39,612,737        
Balances at Sep. 30, 2024                         $ 0 $ 396,127 245,733,382 781,530 (217,466,320) 29,444,719
Exercise of stock options, RSUs & RSAs, net (in shares)                         0 229,097        
Exercise of stock options, RSUs & RSAs, net                         $ 0 $ 2,291 (2,291) 0 0 0
Stock-based compensation on stock options, RSUs & RSAs                         0 0 231,581 0 0 231,581
Foreign currency translation adjustment                         0 0 0 (451,035) 0 (451,035)
Net loss                         $ 0 $ 0 0 0 (2,611,997) (2,611,997)
Balances (in shares) at Dec. 31, 2024                         0 39,890,834        
Balances at Dec. 31, 2024                         $ 0 $ 398,908 246,051,852 330,495 (220,078,317) 26,702,938
Shares issued as compensation (in shares)                         0 49,000        
Shares issued as compensation                         $ 0 $ 490 89,180 0 0 89,670
Balances (in shares) at Jun. 30, 2025                         24,956 42,949,307        
Balances at Jun. 30, 2025                         $ 34,232,510 $ 429,493 244,953,346 978,686 (230,716,757) 15,644,768
Exercise of stock options, RSUs & RSAs, net (in shares)                         0 8,583        
Exercise of stock options, RSUs & RSAs, net                         $ 0 $ 86 (86) 0 0 0
Issuance of common stock under private equity placement (in shares) 0 1,600,000                                
Issuance of common stock under private equity placement $ 0 $ 16,000 $ 7,878,045 $ 0 $ 0 $ 7,894,045                        
Issuance of common stock for acquisition of Visimid (in shares)                         0 112,323        
Issuance of common stock for acquisition of Visimid                         $ 0 $ 1,123 348,877 0 0 350,000
Stock-based compensation on stock options, RSUs & RSAs                         0 0 349,624 0 0 349,624
Foreign currency translation adjustment                         0 0 0 92,383 0 92,383
Net loss                         $ 0 $ 0 0 0 (2,893,002) (2,893,002)
Balances (in shares) at Sep. 30, 2025                         24,956 44,670,213        
Balances at Sep. 30, 2025                         $ 34,232,510 $ 446,702 253,529,806 1,071,069 (233,609,759) 21,437,818
Balances (in shares) at Jun. 30, 2025                         24,956 42,949,307        
Balances at Jun. 30, 2025                         $ 34,232,510 $ 429,493 244,953,346 978,686 (230,716,757) 15,644,768
Foreign currency translation adjustment                                   305,242
Net loss                                   (12,298,411)
Balances (in shares) at Dec. 31, 2025                         24,956 54,442,677        
Balances at Dec. 31, 2025                         $ 34,232,510 $ 544,427 319,121,901 1,283,928 (243,015,168) 77,935,088
Balances (in shares) at Sep. 30, 2025                         24,956 44,670,213        
Balances at Sep. 30, 2025                         $ 34,232,510 $ 446,702 253,529,806 1,071,069 (233,609,759) 21,437,818
Exercise of stock options, RSUs & RSAs, net (in shares)                         0 120,234        
Exercise of stock options, RSUs & RSAs, net                         $ 0 $ 1,203 (1,203) 0 0 0
Issuance of common stock under private equity placement (in shares)             0 8,912,500                    
Issuance of common stock under private equity placement             $ 0 $ 89,125 $ 65,251,709 $ 0 $ 0 $ 65,340,834            
Stock-based compensation on stock options, RSUs & RSAs                         0 0 348,986 0 0 348,986
Foreign currency translation adjustment                         0 0 0 212,859 0 212,859
Net loss                         $ 0 $ 0 0 0 (9,405,409) (9,405,409)
Exercise of warrants (in shares)                         0 739,730        
Exercise of warrants                         $ 0 $ 7,397 (7,397) 0 0 0
Balances (in shares) at Dec. 31, 2025                         24,956 54,442,677        
Balances at Dec. 31, 2025                         $ 34,232,510 $ 544,427 $ 319,121,901 $ 1,283,928 $ (243,015,168) $ 77,935,088